In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product
1996

Anti-tumor effects of a humanized monoclonal antibody

publication Evidence: moderate

Author Information

Author(s): Y Tokuda, Y Ohnishi, K Shimamura, M Iwasawa, M Yoshimura, Y Ueyama, N Tamaoki, T Tajima, T Mitomi

Primary Institution: Tokai University School of Medicine

Hypothesis

The humanized antibody rhu4D5 will show better anti-tumor effects than its murine counterpart mu4D5.

Conclusion

The humanized antibody rhu4D5 demonstrated significant anti-tumor activity in vivo, particularly against c-erbB-2-overexpressing tumors.

Supporting Evidence

  • Rhu4D5 showed potent anti-tumor activity in SCID mice.
  • Cytotoxicity of human PBMC was significantly increased with rhu4D5.
  • Rhu4D5 was less effective than mu4D5 in inhibiting the growth of 4-1ST xenografts.

Takeaway

Scientists tested a new medicine that helps fight cancer, and it worked better than an older version in mice.

Methodology

The study involved in vitro assays on human tumor cell lines and in vivo tests on SCID mice with human gastric cancer xenografts.

Potential Biases

Potential human anti-mouse antibody responses could limit clinical application.

Limitations

The humanized antibody was less effective than the murine version in some tests.

Participant Demographics

SCID mice were used for in vivo testing.

Statistical Information

P-Value

0.066

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication